Viatris Inc. (VTRS) All Metrics
VTRS Valuation Metrics
VTRS Stock Price Metrics
VTRS Dividend Metrics
VTRS Growth Rate Metrics
VTRS Discounted Cash Flow Metrics
| Fair Value Price | $23.62 |
| Margin of Safety | 53.70% |
VTRS Revenue Metrics
VTRS PE Ratio Metrics
| PE Ratio | 295.25 |
| PE Ratio Avg TTM | 6.70 |
| PE Ratio Avg 3Y | 11.06 |
| Current VS TTM Avg | +4307.31% |
| Current VS 3Y Avg | +2568.89% |
| Current VS 5Y Avg | +213.09% |
VTRS PS Ratio Metrics
| PS Ratio | 1.24 |
| PS Ratio Avg TTM | 1.00 |
| PS Ratio Avg 3Y | 0.87 |
| Current VS TTM Avg | +23.42% |
| Current VS 3Y Avg | +42.41% |
| Current VS 5Y Avg | +41.32% |
VTRS PB Ratio Metrics
| PB Ratio | 1.23 |
| PB Ratio Avg TTM | 0.95 |
| PB Ratio Avg 3Y | 0.68 |
| Current VS TTM Avg | +30.00% |
| Current VS 3Y Avg | +80.05% |
| Current VS 5Y Avg | +78.49% |
VTRS Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 10.57 |
| PFCF Ratio Avg TTM | 8.39 |
| PFCF Ratio Avg 3Y | 6.82 |
| Current VS TTM Avg | +26.03% |
| Current VS 3Y Avg | +55.04% |
| Current VS 5Y Avg | +56.29% |
VTRS Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 1.00 |
| Debt/Equity Ratio Avg TTM | 0.89 |
| Debt/Equity Ratio Avg 3Y | 0.90 |
| Current VS TTM Avg | +12.99% |
| Current VS 3Y Avg | +11.11% |
| Current VS 5Y Avg | +2.04% |
VTRS PEG Ratio Metrics
| PEG Ratio | - |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | 1.20 |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | - |
| Current VS 5Y Avg | - |
VTRS FCF Yield
| FCF Yield | 9.46% |
| FCF Yield Avg TTM | 12.46% |
| FCF Yield Avg 3Y | 14.77% |
| Current VS TTM Avg | -24.10% |
| Current VS 3Y Avg | -35.93% |
| Current VS 5Y Avg | -40.84% |
VTRS Earnings Yield
| Earnings Yield | 0.34% |
| Earnings Yield Avg TTM | 15.09% |
| Earnings Yield Avg 3Y | 8.72% |
| Current VS TTM Avg | -97.75% |
| Current VS 3Y Avg | -96.10% |
| Current VS 5Y Avg | -92.56% |
VTRS EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 219.55 |
| Ev/Ebit Ratio Avg TTM | 227.68 |
| Ev/Ebit Ratio Avg 3Y | 35.62 |
| Current VS TTM Avg | -3.57% |
| Current VS 3Y Avg | +516.43% |
| Current VS 5Y Avg | +637.64% |
VTRS EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 11.93 |
| Ev/Ebitda Ratio Avg TTM | 12.37 |
| Ev/Ebitda Ratio Avg 3Y | 8.47 |
| Current VS TTM Avg | -3.58% |
| Current VS 3Y Avg | +40.86% |
| Current VS 5Y Avg | +37.36% |
VTRS EV/Assets Ratio Metrics
| Ev/Assets Ratio | 0.83 |
| Ev/Assets Ratio Avg TTM | 0.74 |
| Ev/Assets Ratio Avg 3Y | 0.65 |
| Current VS TTM Avg | +12.25% |
| Current VS 3Y Avg | +28.53% |
| Current VS 5Y Avg | +26.40% |
VTRS EV/Sales Ratio Metrics
| Ev/Sales Ratio | 2.10 |
| Ev/Sales Ratio Avg TTM | 1.96 |
| Ev/Sales Ratio Avg 3Y | 1.94 |
| Current VS TTM Avg | +7.01% |
| Current VS 3Y Avg | +8.36% |
| Current VS 5Y Avg | +7.42% |
VTRS Current Ratio Metrics
| Current Ratio | 1.30 |
| Current Ratio Avg TTM | 1.48 |
| Current Ratio Avg 3Y | 1.55 |
| Current VS TTM Avg | -11.86% |
| Current VS 3Y Avg | -16.13% |
| Current VS 5Y Avg | -8.45% |
VTRS Quick Ratio Metrics
| Quick Ratio | 0.74 |
| Quick Ratio Avg TTM | 0.86 |
| Quick Ratio Avg 3Y | 1.00 |
| Current VS TTM Avg | -13.95% |
| Current VS 3Y Avg | -25.81% |
| Current VS 5Y Avg | -17.63% |
VTRS ROIC Metrics
| ROIC | (7.95%) |
| ROIC Avg 3Y | (1.19%) |
| ROIC Avg 5Y | (0.87%) |
| Current VS 3Y Avg | +568.07% |
| Current VS 5Y Avg | +819.08% |
| Current VS 10Y Avg | -2029.61% |
VTRS Return on Assets Metrics
| ROA | (9.45) |
| ROA Avg TTM | (5.49) |
| ROA Avg 3Y | (1.68) |
| Current VS TTM Avg | +72.13% |
| Current VS 3Y Avg | +463.34% |
| Current VS 5Y Avg | +460.83% |
VTRS Return on Equity Metrics
| ROE | (23.89) |
| ROE Avg TTM | (13.64) |
| ROE Avg 3Y | (4.29) |
| Current VS TTM Avg | +75.08% |
| Current VS 3Y Avg | +456.88% |
| Current VS 5Y Avg | +445.64% |
VTRS Net Profit Margin Metrics
| Net Profit Margin | (24.58%) |
| Net Profit Margin Avg TTM | (14.44%) |
| Net Profit Margin Avg 3Y | (3.94%) |
| Current VS TTM Avg | +70.22% |
| Current VS 3Y Avg | +524.25% |
| Current VS 5Y Avg | +418.20% |
Last Updated: Sunday, June 21, 2026
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith